Table 2

Summary of novel DES with biodegradable polymer coatings

StentManufacturerPlatform materialStrut thickness (μm)Polymer materialTime of biodegradationCoating location and thicknessDrug elutedDrug releaseCompleted clinical studyPrimary end pointOngoing study
SynergyBoston ScientificPlCr74PLGA3–4 MAbluminal
4 μm
Everolimus50% during 30 daysEVOLVE (N=291)Non-inferiority for in-stent LLL at 6 M compared with SYNERGY ½ dose and PROMUS Element
0.10±0.25 vs 0.13±0.26 vs 0.15±0.34 mm
EVOLVE-II(N=1684)
Multicentre, RCT, SYNERGY vs PROMUS Element
PE: 12M TLF
EVOLVE DAPT
(N∼9000)
SYNERGY
DAPT 3 vs 12 M
PE: CD/MI
OrsiroBiotronikCoCr60PLLA1–2 yearsCircumferential
7 μm
Sirolimus50% during 30 daysBIOFLOW-I
(N=30)
LLL at 9 M
0.05±0.22 mm
BIOSCIENCE
(N=2100)
Multicentre, RCT of Orsiro vs Xience Prime
PE: 12M TLF
BIO-RESORT
(N=3530)
Multicentre, RCT of Orsiro vs Synergy vs Resolute Integrity
PE: 12 M TVF
SORT OUT VII
(N=2314)
Multicentre, RCT of Orsiro vs Nobori
PE: 12 M TLF
BIOFLOW-II
(N=452)
Non-inferiority for in-stent LLL at 9 M compared with Xience Prime
0.10±0.32 vs 0.11±0.29 mm
DESyne BDElixir MedicalCoCr81PDLLA6–9 MCircumferential <3 μmNovolimus90% during 90 daysEXCELLA-BD
(N=146)
Non-inferiority for in-stent LLL at 6 M compared with Endeavour ZES
0.12±0.15 vs 0.67±0.47 mm
ComboOrbusNeichSS100PDLLA, PLGA3 MAbluminal
5 μm
Anti-CD34 antibodies + sirolimus95% during 30 daysREMEDEE (N=183)Non-inferiority for
in-stent LLL at 9 M compared with Taxus Liberté
0.39±0.45 vs 0.44±0.56 mm
MiStentMicellCoCr64PLGA2–3 MCircumferentialCrystalline sirolimus100% during
60 days
DESSOLVE-I (N=30)Single arm
LLL at 8 M
0.09±0.10 mm
DESSOLVE-II (N=184)Non-inferiority for in-stent LLL at 9 M compared with Endeavour DES
0.27±0.46 vs 0.58±0.41 mm
UltimasterTerumoCoCr80PDLLA, PCL3–4 MAbluminal
15 μm
Sirolimus90% during 90 daysCENTURYSingle arm
LLL at 8 M
0.04±0.35 mm
CENTURY-II
(N=1120)
Multicentre, RCT of Ultimaster vs Xience
PE: 9 M TLF
  • CD, cardiac death; CoCr, cobalt chromium; DES, drug eluting stent; LLL, late lumen loss; M, months; MI, myocardial infarction; PCL, polycaprolactone; PDLLA, poly-D, L-lactic acid; PE, primary end point; PlCr, platinum chromium; PLGA, poly-lactic co-glycolic acid; PLLA, poly-L-lactic acid; RCT, randomised controlled trial; ST, stent thrombosis; TLF, target lesion failure; TVF, target vessel failure; ZES, zotarolimus eluting stent.